P136. Randomized, prospective clinical trial to evaluate efficacy and safety in lumbar fusion surgery of implantation of autologous bone marrow mesenchymal cells expanded ex vivo and combined with allogeneic bone tissue, compared with autologous iliac crest graft; part II: clinical findings
Pilar Gonzalez-Tartiere, MSc1; Ana García de Frutos, MD2; Maite T. Ubierna, MD3; Alejandro Del Arco, MD4; Guillem Salo, MD, PhD5; Antonia Matamalas, MD6; Juan José Velázquez, MD Ruth Coll, PhD7; Nuria Ribo, MSc7; Antoni Rivas, MD, PhD8; Juan Bagó, MD, PhD9; Enric Caceres, MD, PhD10
1Vall d'Hebron Research Institute (VHIR), Barcelona, Spain; 2Hospital Vall d'Hebron, Barcelona, Barcelona, Spain; 3German Trias I Pujol, Barcelona, Spain; 4Hospital del Mar, Barcelona, Barcelona, Spain; 5Hospital del Mar, Santpedor, Spain; 6Barcelona, Spain; 7Banc de Sang i Teixits BST, Barcelona, Barcelona, Spain; 8Vall d'Hebron Hospital, Barcelona, Barcelona, Spain; 9Hospital Vall d'Hebron, Barcelona, Barcelona, Spain; 10Hospital Universitari Dexeus, Barcelona, Barcelona, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain11
FDA DEVICE/DRUG STATUS: XCEL-MT-OSTEO-ALPHA (Not approved for this indication)
P137. A 5-year review of hospital costs and reimbursement in the surgical management of degenerative spondylolisthesis
Keith W. Lyons, MD; Christian Klare, MD; Samuel Kunkel, MD1; Mike Bao2; Kevin J. McGuire, MD3; Adam M. Pearson, MD, MS3; William Abdu, MD4
1Lebanon, NH, US; 2NYU Hospital for Joint Diseases, New York, NY, US; 3Dartmouth Hitchcock Medical Center, Lebanon, NH, US; 4Hitchcock Clinic, Lebanon, NH, US
FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.